Trial Profile

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Aug 2026 According to a CervoMed media release, company will present 12-week biomarker data from the first eight participants in its ongoing Phase 2a trial in patients with nfvPPA at ISFTD, taking place October 8-11, 2026, in Philadelphia, Pennsylvania.
09 Jul 2026 According to a CervoMed media release, enrollment in the trial has been completed and company interim biomarker data from study will be presented at the 19thCTAD Conference in Boston, Massachusetts, taking place November 16-19, 2026.
06 Jul 2026 According to a CervoMed media release, company is going to present data from this trial at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15, 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com